Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of 3 Regimens of Chloroquine and Primaquine for Treatment of P. Vivax Malaria, Cruzeiro do Sul, Acre, Brazil

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Age ≥5 years 2. Body weight \<120 kg 3. Documented fever (axillary temperature ≥37.5o C) or history of fever during the previous 48 hours in the absence of another obvious cause of fever, such as pneumonia, otitis media, etc 4. Monoinfection with P. vivax with parasitemia between 100 and 200,000 asexual parasites/µl as determined by microscopic examination of thick and thin peripheral blood smears 5. Informed consent from the patient or parent/guardian (for those \<18 years), assent from child (ages 7 to 17 years inclusive), patients 5 through 6 years old will not need an assent 6. Willingness on the part of the patient to return to the clinic and/or receive home visits for regular check-ups during the 24-week (168 days) follow-up period 7. Place of residence within 30-45 minutes of study site.~Exclusion Criteria:~* 1. Presence of malaria danger signs~  1. Unable to drink~ 2. Vomiting (more than twice in the previous 24 hours)~ 3. Recent history of convulsions (one or more in the previous 24 hours)~ 4. Impaired consciousness~ 5. Unable to sit or stand 2. Presence of signs of severe malaria (WHO criteria)~  <!-- -->~  1. Cerebral malaria (unarousable coma)~ 2. Severe anemia (hematocrit \<15% or clinical signs) hemoglobin \<5 mg/ml) (Note: we will use hemoglobin less than 8 mg/ml as exclusion criteria)~ 3. Renal failure (serum creatinine \>3 mg/dL or clinical signs)~ 4. Pulmonary edema~ 5. Hypoglycemia (blood glucose \<40mg/dL or clinical signs)~ 6. Shock (systolic blood pressure \<70 mm Hg in adults; 50 mm Hg in children)~ 7. Spontaneous bleeding/disseminate intravascular coagulation~ 8. Repeated generalized convulsions~ 9. Acidemia/acidosis (clinical signs)~ 10. Macroscopic hemoglobinuria~ 11. Jaundice 3. Self-reported presence of other underlying chronic or severe diseases (e.g., cardiac, renal, hepatic diseases, HIV/AIDS, tuberculosis, malnutrition, psoriasis) 4. History of hypersensitivity reactions to any of the drugs being tested. Mild itching with CQ is not in itself a criterion for exclusion. This occurrence will be evaluated by the study doctor before excluding the patient for this reason alone.~      5. Use of drugs with antimalarial activity in the past 30 days. (Annex D) 6. Current pregnancy (either self-reported being pregnant at enrollment or a positive urine or plasma pregnancy test at time of enrollment), previous pregnancy is not an exclusion criteria 7. Hemoglobin \<8 mg/mL 8. G6PD deficiency. This will be a late exclusion criteria as soon as the results of G6PD testing becomes available.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Primaquine Regular Dose Unsupervised (Type: OTHER): This is the regular primaquine dose Brazil without directly observed therapy.
- Primaquine Regular Dose Supervised (Type: ACTIVE_COMPARATOR): This is the regular primaquine dose in Brazil but with directly observed therapy.
- Primaquine Double Dose Unsupervised (Type: ACTIVE_COMPARATOR): This is the double total primaquine dose (14 days) in Brazil with directly observed therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete